Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations

Publications

  1. 2024
  2. Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

    Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K., Hanoun, C., Schnitzler, P., Klemm, S., Goldschmidt, H., Raab, M. & Elmaagacli, A., 12.2024, In: HEMATOLOGY. 29, 1, p. 2320006

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    Rodriguez-Otero, P., Usmani, S., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X., Pérez-Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M. V., Einsele, H., Minnema, M., Cavo, M., Derman, B. A., Puig, N., Gay, F., Ho, P. J., Chng, W-J., Kastritis, E., Gahrton, G., Weisel, K., Nagarajan, C., Schjesvold, F., Mikhael, J., Costa, L., Raje, N. S., Zamagni, E., Hájek, R., Weinhold, N., Yong, K., Ye, J. C., Sidhana, S., Merlini, G., Martin, T., Lin, Y., Chari, A., Popat, R., Kaufman, J. L. & International Myeloma Working Group, 05.2024, In: LANCET ONCOL. 25, 5, p. e205-e216

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  4. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., Perualila, N., Gan, R., Zhang, Y., Parekh, T., Albrecht, C., Weisel, K. & Mateos, M-V., 04.2024, In: ADV THER. 41, 4, p. 1576-1593 18 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  5. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

    Mai, E. K., Goldschmid, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Kunz, C., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Benner, A., Seidel-Glätzer, A., Weisel, K. C., Raab, M. S., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators, 02.2024, In: LANCET HAEMATOL. 11, 2, p. e101-e113

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  6. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 01.01.2024, In: J CLIN ONCOL. 42, 1, p. 26-37 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  7. 2023
  8. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials

    Laane, E., Salek, S., Oliva, E. N., Bennink, C., Clavreul, S., Richardson, P. G., Scheid, C., Weisel, K., Ionova, T. & European Hematology Association Specialized Working Group on Quality of Life and Symptoms, 08.12.2023, In: CANCERS. 15, 24, 5764.

    Research output: SCORING: Contribution to journalGuideline, recommendation, statementResearchpeer-review

  9. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

    Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  10. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  11. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

    Leypoldt, L. B., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M. S., Nogai, A., Khandanpour, C., Runde, V., Jauch, A., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M. A. & Weisel, K. C., 21.09.2023, In: CANCERS. 15, 18, 4667.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  12. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  13. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Ramasamy, K., Avet-Loiseau, H., Hveding Blimark, C., Delforge, M., Gay, F., Manier, S., Martinez-Lopez, J., Mateos, M. V., Mohty, M., van de Donk, N. W. C. J. & Weisel, K., 09.2023, In: HEMASPHERE. 7, 9, p. e942

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  14. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

    Manier, S., Dimopoulos, M., Hulin, C., Leleu, X., Delforge, M., Weisel, K., Mouro, J., Costa, B., Sturniolo, M. & Facon, T., 09.2023, In: CL LYMPH MYELOM LEUK. 23, 9, p. e297-e306.e1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  15. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Mateos, M-V., Weisel, K., Martin, T., Berdeja, J. G., Jakubowiak, A., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., Thilakarathne, P., Perualila, N. J., Cabrieto, J., Haefliger, B., Erler-Yates, N., Hague, C., Jackson, C. C., Schecter, J. M., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H. & Moreau, P., 01.08.2023, In: HAEMATOLOGICA. 108, 8, p. 2192-2204 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  16. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Usmani, S. Z., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D. S., Weisel, K. C., Shu, X., Li, C. & Dimopoulos, M. A., 25.07.2023, In: BLOOD ADV. 7, 14, p. 3739-3748 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  17. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  18. What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland

    Giesler, M., Busson-Spielberger, M., Miemietz, B., de Wit, M., Weisel, K. & Lüftner, D., 07.2023, In: J CANCER RES CLIN. 149, 8, p. 5331-5344 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  19. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Ludwig, H., Terpos, E., van de Donk, N., Mateos, M-V., Moreau, P., Dimopoulos, M-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M. & Sonneveld, P., 06.2023, In: LANCET ONCOL. 24, 6, p. e255-e269

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  20. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Moreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., De Stefano, V., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., Leleu, X., Weisel, K., Ghilotti, F., Diels, J., Elsada, A., Morano, R., Strulev, V., Pei, L., Kobos, R., Smit, J., Slavcev, M. & Mateos, M-V., 05.2023, In: ADV THER. 40, 5, p. 2412-2425 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  21. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Mateos, M-V., Chari, A., Usmani, S. Z., Goldschmidt, H., Weisel, K., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M. & Moreau, P., 05.2023, In: CL LYMPH MYELOM LEUK. 23, 5, p. 385-393 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  22. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

    Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H., Weisel, K. C. & Raab, M. S., 06.04.2023, In: BLOOD. 141, 14, p. 1685-1690 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  23. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., Macro, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., Vermeulen, J., Duran, J., Borgsten, F. & Usmani, S. Z., 04.2023, In: FUTURE ONCOL. 19, 13, p. 887-895 9 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  24. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Levin, M-D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R. & Spencer, A., 10.03.2023, In: J CLIN ONCOL. 41, 8, p. 1600-1609 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  25. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

    Weisel, K., Dimopoulos, M. A., San-Miguel, J., Paner, A., Engelhardt, M., Taylor, F., Lord-Bessen, J., Yip, C., Greenwood, M., Tang, J. & Cavo, M., 03.2023, In: HEMASPHERE. 7, 3, p. e843

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  26. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

    Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S-P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., Omel, J., Spencer, A., Terpos, E., Hungria, V. T. M., Puig, N., Fu, C., Ferrari, R. H., Ren, K., Stull, D. M. & Chari, A., 03.2023, In: CL LYMPH MYELOM LEUK. 23, 3, p. e171-e181

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  27. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

    Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y-M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I. & Jagannath, S., 02.2023, In: CL LYMPH MYELOM LEUK. 23, 2, p. 112-122 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  28. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

    Mai, E. K., Huhn, S., Miah, K., Poos, A. M., Scheid, C., Weisel, K. C., Bertsch, U., Munder, M., Berlanga, O., Hose, D., Seckinger, A., Jauch, A., Blau, I. W., Hänel, M., Salwender, H. J., Benner, A., Raab, M. S., Goldschmidt, H. & Weinhold, N., 04.01.2023, In: BLOOD CANCER J. 13, 1, p. 1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  29. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  30. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Rodríguez Otero, P., Towle, K., Cope, S., Caisip, C., Davies, F. E., Delforge, M., Weisel, K., Marshall, T. S., Karampampa, K., Ayers, D., Mojebi, A., Braverman, J., Farrell, J. & Dhanda, D., 2023, In: LEUKEMIA LYMPHOMA. 64, 11, p. 1864-1869 6 p.

    Research output: SCORING: Contribution to journalLetterResearchpeer-review

  31. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

    Emde-Rajaratnam, M., Beck, S., Benes, V., Salwender, H., Bertsch, U., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Maes, K., De Bruyne, E., Menu, E., De Veirman, K., Moreaux, J., Vanderkerken, K., Seckinger, A. & Hose, D., 2023, In: FRONT IMMUNOL. 14, p. 1286700

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  32. 2022
  33. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  34. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  35. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., Abdallah, A-O., Badros, A. Z., Knop, S., Stadtmauer, E. A., Cheng, Y., Amatangelo, M., Chen, M., Nguyen, T. V., Amin, A., Peluso, T. & van de Donk, N. W. C. J., 11.2022, In: LANCET HAEMATOL. 9, 11, p. e822-e832

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  36. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M. & Cohen, Y. C., 01.10.2022, In: CL LYMPH MYELOM LEUK. 22, Suppl 2, S411.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  37. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  38. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  39. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    Weisel, K., Wadlund, A. O., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N. & Rodriguez-Otero, P., 10.2022, In: EUR J HAEMATOL. 109, 4, p. 388-397 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  40. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T-M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S. & Martin, T., 09.2022, In: CL LYMPH MYELOM LEUK. 22, 9, p. 690-701 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  41. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., Mollee, P., Kim, J. S., Shu, N., Hu, X., Li, C. & Usmani, S. Z., 09.2022, In: BRIT J HAEMATOL. 198, 6, p. 988-993 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  42. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

    Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  43. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

    Modemann, F., Ghandili, S., Schmiedel, S., Weisel, K., Bokemeyer, C. & Fiedler, W., 29.07.2022, In: CANCERS. 14, 15, 3711.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  44. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  45. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

    Schönlein, M., Wrage, V., Ghandili, S., Mellinghoff, S. C., Brehm, T. T., Leypoldt, L. B., Utz, N., Schrader, R. M., Alsdorf, W., Börschel, N., Bußmann, L., Schönrock, M., Perlick, D., Schön, G., Verpoort, K., Lütgehetmann, M., Schulze Zur Wiesch, J., Weisel, K. C., Bokemeyer, C., Schafhausen, P. & Sinn, M., 13.06.2022, In: CANCER CELL. 40, 6, p. 581-583 3 p.

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  46. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  47. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Mateos, M-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. & Moreau, P., 05.2022, In: LEUKEMIA. 36, 5, p. 1371-1376 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  48. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

    Piechotta, V., Skoetz, N., Engelhardt, M., Einsele, H., Goldschmidt, H., Scheid, C. & guideline group, 08.04.2022, In: DTSCH ARZTEBL INT. 119, 14, p. 253-260 8 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  49. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

    Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Hebraud, B., Belhadj-Merzoug, K., Benboubker, L., Decaux, O., Manier, S., Caillot, D., Ukropec, J., Pei, H., Van Rampelbergh, R., Uhlar, C. M., Kobos, R. & Zweegman, S., 04.2022, In: LEUKEMIA. 36, 4, p. 1066-1077 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  50. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies

    Modemann, F., Niederwieser, C., Weisel, K., Bokemeyer, C., Fiedler, W. & Ghandili, S., 03.2022, In: LEUKEMIA LYMPHOMA. 63, 3, p. 664-671 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  51. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

    Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  52. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

    Cavo, M., San-Miguel, J. F. F., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A. A., Avet-Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V. T. D. M., Moreau, P., Mateos, M. V., Perrot, A., Iida, S., Facon, T., Kumar, S. K., van de Donk, N. W. C. J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M. & Munshi, N. C., 10.02.2022, In: BLOOD. 139, 6, p. 835-844 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  53. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

    Martin, T., Krishnan, A., Yong, K., Weisel, K., Mehra, M., Nair, S., Qi, K., Londhe, A., Diels, J., Crivera, C., Jackson, C. C., Olyslager, Y., Vogel, M., Schecter, J. M., Banerjee, A., Valluri, S., Usmani, S. Z., Berdeja, J. G. & Jagannath, S., 02.2022, In: EJHaem. 3, 1, p. 97-108 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  54. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

    Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K. C., Scheid, C., Keller, U., Hose, D. & Bassermann, F., 25.01.2022, In: BLOOD ADV. 6, 2, p. 515-520 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  55. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    Weisel, K., Martin, T., Krishnan, A., Jagannath, S., Londhe, A., Nair, S., Diels, J., Vogel, M., Schecter, J. M., Banerjee, A., Berdeja, J. G., Nesheiwat, T., Garrett, A., Qi, K., Valluri, S., Usmani, S. Z. & Yong, K., 01.2022, In: CLIN DRUG INVEST. 42, 1, p. 29-41 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  56. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

    Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., Rodriguez-Otero, P., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Beksac, M., Oriol, A., Lindsay, J., Liberati, A. M., Galli, M., Robak, P., Larocca, A., Yagci, M., Vural, F., Kanate, A. S., Jiang, R., Grote, L., Peluso, T. & Dimopoulos, M., 01.2022, In: EUR J HAEMATOL. 108, 1, p. 73-83 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  57. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

    Pape, L. J., Hambach, J., Gebhardt, A. J., Rissiek, B., Stähler, T., Tode, N., Khan, C., Weisel, K., Adam, G., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 1010270.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  58. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

    Hambach, J., Fumey, W., Stähler, T., Gebhardt, A. J., Adam, G., Weisel, K., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 838406.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  59. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

    Krohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K., Gramatzki, M., Peipp, M. & Klausz, K., 2022, In: FRONT IMMUNOL. 13, 908093.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  60. 2021
  61. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M-V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Schreder, M., Abildgaard, N., Hajek, R., Zojer, N., Kastritis, E., Broijl, A., Schjesvold, F., Boccadoro, M. & Terpos, E., 12.2021, In: LANCET HAEMATOL. 8, 12, p. e934-e946

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  62. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

    Siegel, D., Weisel, K., Zahlten-Kumeli, A., Medhekar, R., Ding, B. & Leleu, X., 12.2021, In: LEUKEMIA LYMPHOMA. 62, 12, p. 3002-3010 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  63. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

    Ghandili, S., Weisel, K. C., Bokemeyer, C. & Leypoldt, L. B., 16.11.2021, In: ONCOL RES TREAT. 44, 12, p. 690-699 10 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  64. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Sborov, D., Suvannasankha, A., Weisel, K., Voorhees, P. M., Womersley, L., Baron, J., Piontek, T., Lewis, E., Opalinska, J., Gupta, I. & Cohen, A. D., 15.11.2021, In: CANCER-AM CANCER SOC. 127, 22, p. 4198-4212 15 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  65. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  66. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Tromp, B., Delioukina, M., Vermeulen, J. & Usmani, S. Z., 11.2021, In: LANCET ONCOL. 22, 11, p. 1582-1596 15 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  67. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

    Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., Fuhrmann, S., Lindemann, H-W., Weisel, K., Duerig, J. & Goldschmidt, H., 10.2021, In: LEUKEMIA. 35, 10, p. 3007-3011 5 p.

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  68. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

    Rodriguez-Otero, P., Ayers, D., Cope, S., Davies, F. E., Delforge, M., Mojebi, A., Jansen, J. P., Weisel, K., Hege, K. & Dhanasiri, S., 10.2021, In: LEUKEMIA LYMPHOMA. 62, 10, p. 2482-2491 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  69. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

    Klein, E-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Raab, M. S., Blau, I. W., Haenel, M., Scheid, C., Goldschmidt, H. & On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg, 28.09.2021, In: CANCERS. 13, 19, p. 4856

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  70. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

    Ramasamy, K., Gay, F., Weisel, K., Zweegman, S., Mateos, M. V. & Richardson, P., 09.2021, In: Blood reviews. 49, p. 100808

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  71. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

    Davies, F., Rifkin, R., Costello, C., Morgan, G., Usmani, S., Abonour, R., Palumbo, A., Romanus, D., Hajek, R., Terpos, E., Cherepanov, D., Stull, D. M., Huang, H., Leleu, X., Berdeja, J., Lee, H. C., Weisel, K., Thompson, M., Boccadoro, M., Zonder, J., Cook, G., Puig, N., Vela-Ojeda, J., Farrelly, E., Raju, A., Blazer, M. & Chari, A., 09.2021, In: ANN HEMATOL. 100, 9, p. 2325-2337 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  72. Selective elimination of immunosuppressive T cells in patients with multiple myeloma

    Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A., Weisel, K., Maier, B., Weinhold, N., Salwender, H. J., Eckstein, V., Hänel, M., Fenk, R., Dürig, J., Brors, B., Benner, A., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 09.2021, In: LEUKEMIA. 35, 9, p. 2602-2615 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  73. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    Quach, H., Nooka, A., Samoylova, O., Venner, C. P., Kim, K., Facon, T., Spencer, A., Usmani, S. Z., Grosicki, S., Suzuki, K., Delimpasi, S., Weisel, K., Obreja, M., Zahlten-Kumeli, A. & Mateos, M-V., 08.2021, In: BRIT J HAEMATOL. 194, 4, p. 784-788 5 p.

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  74. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation

    Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., Weisel, K. C., Bokemeyer, C. & Janjetovic, S., 21.07.2021, In: ONCOL RES TREAT. 44, 7-8, p. 375-381 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  75. 56/m mit Rückenschmerzen und Konzentrationsstörungen

    Leypoldt, L. B. & Weisel, K. C., 12.07.2021, In: ONKOLOGE. 2021, 27 supplement issue 1, p. 27-32

    Research output: SCORING: Contribution to journalSCORING: Journal articleEducation

  76. Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

    Hájek, R., Minařík, J., Straub, J., Pour, L., Jungova, A., Berdeja, J. G., Boccadoro, M., Brozova, L., Spencer, A., Rhee, F. V., Vela-Ojeda, J., Thompson, M. A., Abonour, R., Chari, A., Cook, G., Costello, C. L., Davies, F. E., Hungria, V. T., Lee, H. C., Leleu, X., Puig, N., Rifkin, R. M., Terpos, E., Usmani, S. Z., Weisel, K. C., Zonder, J. A., Bařinová, M., Kuhn, M., Šilar, J., Čápková, L., Galvez, K., Lu, J., Elliott, J., Stull, D. M., Ren, K. & Maisnar, V., 07.2021, In: FUTURE ONCOL. 17, 19, p. 2499-2512 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  77. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., de Oca, R. M., Paul, S., Holkova, B., Gupta, I., Kremer, B. E. & Richardson, P., 06.2021, In: FUTURE ONCOL. 17, 16, p. 1987-2003 17 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  78. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

    Weisel, K., Mateos, M-V., Gay, F., Delforge, M., Cook, G., Szabo, Z., Desgraz, R., DeCosta, L. & Moreau, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1732-1744 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  79. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Dimopoulos, M., Weisel, K., Moreau, P., Anderson, L. D., White, D., San-Miguel, J., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Casal, E., Srinivasan, S., Yu, X., Nguyen, T. V., Biyukov, T., Peluso, T. & Richardson, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1722-1731 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  80. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    Hungria, V., Beksac, M., Weisel, K. C., Nooka, A. K., Masszi, T., Spicka, I., Munder, M., Mateos, M-V., Mark, T. M., Qi, M., Qin, X., Fastenau, J., Spencer, A., Sonneveld, P., Garvin, W., Renaud, T. & Gries, K. S., 05.2021, In: BRIT J HAEMATOL. 193, 3, p. 561-569 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  81. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

    Avet-Loiseau, H., San-Miguel, J., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A., Moreau, P., Plesner, T., Weisel, K., Ukropec, J., Chiu, C., Trivedi, S., Amin, H., Krevvata, M., Ramaswami, P., Qin, X., Qi, M., Sun, S., Qi, M., Kobos, R. & Bahlis, N. J., 01.04.2021, In: J CLIN ONCOL. 39, 10, p. 1139-1149 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  82. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

    Goldschmidt, H., Baertsch, M-A., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M-S., Hillengass, J., Sauer, S., Müller-Tidow, C., Luntz, S., Jauch, A., Hose, D., Seckinger, A., Brossart, P., Goerner, M., Klein, S., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Haenel, M., Martin, H., Lindemann, H. W., Scheid, C., Nogai, A., Salwender, H., Noppeney, R., Besemer, B., Weisel, K. & German Myeloma Multicenter Group (GMMG), 04.2021, In: LEUKEMIA. 35, 4, p. 1134-1144 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  83. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    Radocha, J., van de Donk, N. W. C. J. & Weisel, K., 29.03.2021, In: CANCERS. 13, 7, p. 1551

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  84. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

    Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H-W., Merz, M., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M. S., Blau, I. W., Hänel, M., Benner, A., Salwender, H. J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 03.2021, In: LEUKEMIA. 35, 3, p. 809-822 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  85. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., Cavo, M., Kristinsson, S. Y., Lentzsch, S., Hajek, R., Anderson, K. C., João, C., Einsele, H., Sonneveld, P., Engelhardt, M., Fonseca, R., Vangsted, A., Weisel, K., Baz, R., Hungria, V., Berdeja, J. G., Leal da Costa, F., Maiolino, A., Waage, A., Vesole, D. H., Ocio, E. M., Quach, H., Driessen, C., Bladé, J., Leleu, X., Riva, E., Bergsagel, P. L., Hou, J., Chng, W. J., Mellqvist, U-H., Dytfeld, D., Harousseau, J-L., Goldschmidt, H., Laubach, J., Munshi, N. C., Gay, F., Beksac, M., Costa, L. J., Kaiser, M., Hari, P., Boccadoro, M., Usmani, S. Z., Zweegman, S., Holstein, S., Harrison, S., Nahi, H., Cook, G., Mateos, M-V., Rajkumar, S. V., Dimopoulos, M. A. & Richardson, P. G., 03.2021, In: LANCET ONCOL. 22, 3, p. e105-e118

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  86. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K. & San-Miguel, J., 25.02.2021, In: NEW ENGL J MED. 384, 8, p. 705-716 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  87. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Terpos, E., Mikhael, J., Hajek, R., Chari, A., Zweegman, S., Lee, H. C., Mateos, M-V., Larocca, A., Ramasamy, K., Kaiser, M., Cook, G., Weisel, K. C., Costello, C. L., Elliott, J., Palumbo, A. & Usmani, S. Z., 18.02.2021, In: BLOOD CANCER J. 11, 2, p. 40

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  88. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

    Chari, A., Munder, M., Weisel, K., Jenner, M., Bygrave, C., Petrucci, M. T., Boccadoro, M., Cavo, M., van de Donk, N. W. C. J., Turgut, M., Demirkan, F., Karadogan, I., Libby, E., Kleiman, R., Kuppens, S., Bandekar, R., Neff, T., Heuck, C., Qi, M., Clemens, P. L. & Goldschmidt, H., 02.2021, In: ADV THER. 38, 2, p. 1328-1341 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  89. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

    Moreau, P., Hebraud, B., Facon, T., Leleu, X., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., Merz, M., Weisel, K., Salwender, H., Mai, E. K., Goldschmidt, H., Bertsch, U., Vanquickelberghe, V., Kampfenkel, T., Boer, C. D., Krotneva, S., Proskorovsky, I., He, J., Lam, A., Lee, C., Cote, S. & Sonneveld, P., 02.2021, In: IMMUNOTHERAPY-UK. 13, 2, p. 143-154 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  90. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

    Perrot, A., Facon, T., Plesner, T., Usmani, S. Z., Kumar, S., Bahlis, N. J., Hulin, C., Orlowski, R. Z., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., He, J., Ho, K. F., Van Rampelbergh, R., Uhlar, C. M., Wang, J., Kobos, R., Gries, K. S., Fastenau, J. & Weisel, K., 20.01.2021, In: J CLIN ONCOL. 39, 3, p. 227-237 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  91. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

    Baertsch, M-A., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., Schlenzka, J., Kunz, C., Raab, M. S., Hillengaß, J., Jauch, A., Seckinger, A., Hose, D., Luntz, S., Sonneveld, P., Lokhorst, H., Martin, H., Goerner, M., Hoffmann, M., Lindemann, H-W., Bernhard, H., Blau, I. W., Scheid, C., Besemer, B., Weisel, K. C., Hänel, M., Dürig, J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 07.01.2021, In: BLOOD CANCER J. 11, 1, p. 1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  92. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Boccadoro, M., Moreau, P., San-Miguel, J., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T., Driessen, C., Hajek, R., Dimopoulos, M. A., Gay, F., Avet-Loiseau, H., Terpos, E., Zojer, N., Mohty, M., Mateos, M-V., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., Engelhardt, M., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Abildgaard, N., Bringhen, S. & Sonneveld, P., 01.2021, In: LEUKEMIA. 35, 1, p. 31-44 14 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  93. 2020
  94. Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients

    Ghandili, S., Pfefferle, S., Roedl, K., Sonnemann, P., Karagiannis, P., Boenisch, O., Kluge, S., Schmiedel, S., Ittrich, H., Rohde, H., Lütgehetmann, M., Weisel, K., Bokemeyer, C., Wichmann, D., Fiedler, W., Jarczak, D. & Modemann, F., 08.12.2020, In: Blood Adv. 4, 23, p. 5936-5941 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  95. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

    Facon, T., Niesvizky, R., Mateos, M-V., Siegel, D., Rosenbaum, C., Bringhen, S., Weisel, K., Ho, P. J., Ludwig, H., Kumar, S., Wang, K., Obreja, M., Yang, Z., Klippel, Z., Mezzi, K., Goldrick, A., Tekle, C. & Dimopoulos, M. A., 10.11.2020, In: BLOOD ADV. 4, 21, p. 5449-5459 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  96. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

    Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K. L., Hungria, V. T. D. M., Engelhardt, M., Gay, F., Garcia-Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C. A., Kumar, S. K., Stadtmauer, E., Einsele, H., Beksac, M., Weisel, K. C., Anderson, K. C., Mateos, M-V., Moreau, P., San Miguel, J., Munshi, N. C. & Avet-Loiseau, H., 06.11.2020, In: BLOOD.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  97. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    Goldschmidt, H., Dimopoulos, M. A., Rajkumar, S. V., Weisel, K. C., Moreau, P., Chng, W-J., Mikala, G., Cavo, M., Ramasamy, K., Suryanarayan, K., Teng, Z., Labotka, R. & Mateos, M. V., 11.2020, In: LEUKEMIA. 34, 11, p. 3019-3027 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  98. Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

    Yan, X., Xu, X. S., Weisel, K. C., Mateos, M-V., Sonneveld, P., Dimopoulos, M. A., Usmani, S. Z., Bahlis, N. J., Puchalski, T., Ukropec, J., Bellew, K., Ming, Q., Sun, S. & Zhou, H., 11.2020, In: CTS-CLIN TRANSL SCI. 13, 6, p. 1345-1354 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  99. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

    Jansen, L., Merz, M., Engelhardt, M., Weisel, K., Scheid, C., Straka, C., Langer, C., Salwender, H., Einsele, H., Kröger, N., Beelen, D. W., Dreger, P., Goldschmidt, H., Brenner, H. & German National Registry for Stem Cell Transplants (DRST), 10.2020, In: LEUKEMIA LYMPHOMA. 61, 10, p. 2365-2374 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  100. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., Shpilberg, O., Grosicki, S., Špička, I., Walter-Croneck, A., Magen, H., Mateos, M-V., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Matsumoto, M., Wu, K. L., Anderson, K. C., Jou, Y-M., Ganetsky, A., Singhal, A. K. & Richardson, P. G., 04.09.2020, In: BLOOD CANCER J. 10, 9, p. 91

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  101. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

    Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D. T., Jakubowiak, A., Dingli, D., Cornell, R. F., Hofmeister, C. C., Siegel, D., Berdeja, J. G., Reece, D., White, D., Lentzsch, S., Gasparetto, C., Huff, C. A., Jagannath, S., Baz, R., Nooka, A. K., Richter, J., Abonour, R., Parker, T. L., Yee, A. J., Moreau, P., Lonial, S., Tuchman, S., Weisel, K. C., Mohty, M., Choquet, S., Unger, T. J., Li, K., Chai, Y., Li, L., Shah, J., Shacham, S., Kauffman, M. G. & Dimopoulos, M. A., 09.2020, In: LEUKEMIA. 34, 9, p. 2430-2440 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  102. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M-D., Bosi, A., Hungria, V., Cavo, M., Lee, J-J., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., Min, C-K., Chanan-Khan, A. A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J-C., Shin, H-J., Sonneveld, P., Casneuf, T., DeAngelis, N., Amin, H., Ukropec, J., Kobos, R. & Mateos, M-V., 20.08.2020, In: J HEMATOL ONCOL. 13, 1, p. 115

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  103. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

    Kriegsmann, K., Hundemer, M., Hofmeister-Mielke, N., Reichert, P., Manta, C-P., Awwad, M. H. S., Sauer, S., Bertsch, U., Besemer, B., Fenk, R., Hänel, M., Munder, M., Weisel, K. C., Blau, I. W., Neubauer, A., Müller-Tidow, C., Raab, M. S., Goldschmidt, H., Huhn, S. & For The German-Speaking Myeloma Multicenter Group Gmmg, 18.08.2020, In: CANCERS. 12, 8

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  104. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    Weisel, K., Dimopoulos, M., Moreau, P., Yagci, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P., Byeff, P., Hus, M., Rodríguez-Otero, P., Muelduer, E., Anttila, P., Hayden, P. J., Krauth, M-T., Lucio, P., Ben-Yehuda, D., Mendeleeva, L., Guo, S., Yu, X., Grote, L., Biyukov, T., Dhanasiri, S. & Richardson, P., 08.2020, In: LEUKEMIA LYMPHOMA. 61, 8, p. 1850-1859 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  105. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  106. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

    Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., Lindemann, H-W., Hügle-Dörr, B., Tichy, D., Giesen, N., Hose, D., Seckinger, A., Huhn, S., Luntz, S., Jauch, A., Elmaagacli, A., Rabold, B., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Hoffmann, M., Hillengass, J., Raab, M. S., Blau, I. W., Hänel, M., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG), 07.2020, In: LEUKEMIA. 34, 7, p. 1853-1865 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  107. Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis

    Karagiannis, P., Sänger, L., Alsdorf, W., Weisel, K., Fiedler, W., Kluge, S., Wichmann, D., Bokemeyer, C. & Fuhrmann, V., 24.06.2020, In: CANCERS. 12, 6, 1678.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  108. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Vij, R., Nath, R., Afar, D. E. H., Mateos, M. V., Berdeja, J. G., Raab, M. S., Guenther, A., Martinez-Lopez, J., Jakubowiak, A. J., Leleu, X., Weisel, K., Wong, S., Gulbranson, S., Sheridan, J. P., Reddy, A., Paiva, B., Singhal, A., San-Miguel, J. F. & Moreau, P., 15.05.2020, In: CLIN CANCER RES. 26, 10, p. 2308-2317 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  109. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

    Raab, M. S., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., Weisel, K., Winderlich, M., Griese, J., Härtle, S., Weirather, J., Jarutat, T., Peschel, C. & Chatterjee, M., 05.2020, In: LANCET HAEMATOL. 7, 5, p. e381-e394

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  110. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Cope, S., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M-V., Weisel, K. & Jansen, J. P., 04.2020, In: VALUE HEALTH. 23, 4, p. 441-450 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  111. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

    Dimopoulos, M. A., Niesvizky, R., Weisel, K., Siegel, D. S., Hajek, R., Mateos, M-V., Cavo, M., Huang, M., Zahlten-Kumeli, A. & Moreau, P., 09.03.2020, In: BLOOD CANCER J. 10, 3, p. 35

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  112. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis

    Ramasamy, K., Dhanasiri, S., Thom, H., Buchanan, V., Robinson, S., D'Souza, V. K. & Weisel, K., 03.2020, In: LEUKEMIA LYMPHOMA. 61, 3, p. 668-679 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  113. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

    Bilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K., Besemer, B., Marcu, A., Lübke, M., Schuhmacher, J., Neidert, M. C., Rammensee, H-G., Stevanović, S. & Walz, J. S., 28.02.2020, In: BLOOD CANCER J. 10, 2, p. 24

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  114. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

    Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., Spencer, A., Huang, J. S. Y., Lu, J., Sunami, K., Iida, S., Chng, W-J., Holstein, S. A., Rocci, A., Skacel, T., Labotka, R., Palumbo, A. & Anderson, K. C., 13.02.2020, In: BLOOD CANCER J. 10, 2, p. 17

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  115. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P. & Cohen, A. D., 02.2020, In: LANCET ONCOL. 21, 2, p. 207-221 15 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  116. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

    Ludwig, H., Pönisch, W., Knop, S., Egle, A., Hinke, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Rumpold, H., Pour, L., Jelinek, T., Krenosz, K. J., Meckl, A., Nolte, S., Melchardt, T., Greil, R. & Zojer, N., 02.2020, In: LEUKEMIA LYMPHOMA. 61, 2, p. 377-386 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  117. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma

    Schieferdecker, A., Hörber, S., Ums, M., Besemer, B., Bokemeyer, C., Peter, A. & Weisel, K., 09.01.2020, In: BLOOD CANCER J. 10, 1, p. 2

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  118. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

    Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z. & Dimopoulos, M., 01.2020, In: LEUKEMIA LYMPHOMA. 61, 1, p. 37-46 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  119. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

    Weisel, K., Ludwig, H., Rieth, A., Lebioda, A. & Goldschmidt, H., 01.2020, In: QUAL LIFE RES. 29, 1, p. 69-79 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  120. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Mateos, M-V., Spencer, A., Nooka, A. K., Pour, L., Weisel, K., Cavo, M., Laubach, J. P., Cook, G., Iida, S., Benboubker, L., Usmani, S. Z., Yoon, S-S., Bahlis, N. J., Chiu, C., Ukropec, J., Schecter, J. M., Qin, X., O' Rourke, L. & Dimopoulos, M. A., 2020, In: HAEMATOLOGICA. 105, 2, p. 468-477 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  121. 2019
  122. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

    Mateos, M-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C-K., Medvedova, E., Weisel, K., Chiu, C., Schecter, J. M., Amin, H., Qin, X., Ukropec, J., Kobos, R. & Spencer, A., 09.10.2019, In: CL LYMPH MYELOM LEUK.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  123. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

    Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Krenosz, K. J., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Melchardt, T., Greil, R. & Zojer, N., 10.2019, In: BRIT J CANCER. 121, 9, p. 751-757 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  124. Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

    Merz, M., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Jauch, A., Sauer, S., Luntz, S., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H-W., Dürig, J., Scheid, C., Haenel, M., Weisel, K., Weber, T., Delorme, S., Goldschmidt, H. & Hillengass, J., 27.08.2019, In: BLOOD CANCER J. 9, 9, p. 71

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  125. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F., Kaminetzky, D., Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22.08.2019, In: NEW ENGL J MED. 381, 8, p. 727-738 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  126. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?

    Schieferdecker, A., Binder, M., Weisel, K. & Bokemeyer, C., 07.2019, In: DEUT MED WOCHENSCHR. 144, 14, p. 982-989 8 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  127. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

    Hose, D., Beck, S., Salwender, H., Emde, M., Bertsch, U., Kunz, C., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Moreaux, J. & Seckinger, A., 26.06.2019, In: J HEMATOL ONCOL. 12, 1, p. 65

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  128. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., San Miguel, J., Sunami, K., O'Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M. & OPTIMISMM trial investigators, 06.2019, In: LANCET ONCOL. 20, 6, p. 781-794 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  129. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., Usmani, S. Z. & MAIA Trial Investigators, 30.05.2019, In: NEW ENGL J MED. 380, 22, p. 2104-2115 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  130. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

    Salwender, H., Bertsch, U., Weisel, K., Duerig, J., Kunz, C., Benner, A., Blau, I. W., Raab, M. S., Hillengass, J., Hose, D., Huhn, S., Hundemer, M., Andrulis, M., Jauch, A., Seidel-Glaetzer, A., Lindemann, H-W., Hensel, M., Fronhoffs, S., Martens, U., Hansen, T., Wattad, M., Graeven, U., Munder, M., Fenk, R., Haenel, M., Scheid, C. & Goldschmidt, H., 28.05.2019, In: BMC CANCER. 19, 1, p. 504

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  131. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

    Costello, C., Davies, F. E., Cook, G., Vela-Ojeda, J., Omel, J., Rifkin, R. M., Berdeja, J., Puig, N., Usmani, S. Z., Weisel, K., Zonder, J. A., Terpos, E., Spencer, A., Leleu, X., Boccadoro, M., Thompson, M. A., Romanus, D., Stull, D. M. & Hungria, V., 05.2019, In: FUTURE ONCOL. 15, 13, p. 1411-1428 18 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  132. Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

    Weisel, K. C., Scheid, C., Zago, M., Besemer, B., Mai, E. K., Haenel, M., Duerig, J., Munder, M., Lindemann, H-W., Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Salwender, H. & Goldschmidt, H., 08.04.2019, In: BLOOD CANCER J. 9, 4, p. 45

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  133. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

    Hutchison, C. A., Cockwell, P., Moroz, V., Bradwell, A. R., Fifer, L., Gillmore, J. D., Jesky, M. D., Storr, M., Wessels, J., Winearls, C. G., Weisel, K., Heyne, N. & Cook, M., 04.2019, In: LANCET HAEMATOL. 6, 4, p. e217-e228

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  134. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

    Holstein, S. A., Ye, J. C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., Landgren, C. O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K. & McCarthy, P. L., 03.2019, In: BIOL BLOOD MARROW TR. 25, 3, p. e89-e97

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  135. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

    Ludwig, H., Moreau, P., Dimopoulos, M. A., Mateos, M-V., Kaiser, M., Hajek, R., Feng, S., Cocks, K., Buchanan, J. & Weisel, K., 22.02.2019, In: BLOOD CANCER J. 9, 3, p. 23

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  136. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

    Gonzalez-McQuire, S., Dimopoulos, M-A., Weisel, K., Bouwmeester, W., Hájek, R., Campioni, M., Bennison, C., Xu, W., Pantiri, K., Hensen, M., Terpos, E. & Knop, S., 08.02.2019, In: MDM POLICY PRACT. 4, 1, p. 2381468318814253

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  137. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

    Qian, X., Dimopoulos, M. A., Amatangelo, M., Bjorklund, C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., Sternas, L., Zaki, M., Moreau, P. & Thakurta, A., 02.2019, In: LEUKEMIA LYMPHOMA. 60, 2, p. 462-470 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  138. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

    Kriegsmann, K., Baertsch, M-A., Awwad, M. H. S., Merz, M., Hose, D., Seckinger, A., Jauch, A., Becker, N., Benner, A., Raab, M. S., Hillengass, J., Bertsch, U., Dürig, J., Salwender, H. J., Hänel, M., Fenk, R., Munder, M., Weisel, K., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 29.01.2019, In: BLOOD CANCER J. 9, 2, p. 13

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  139. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W-J., Kaiser, M., Zweegman, S., Mateos, M-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V. & TOURMALINE-MM3 study group, 19.01.2019, In: LANCET. 393, 10168, p. 253-264 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  140. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

    Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 01.2019, In: LEUKEMIA LYMPHOMA. 60, 1, p. 151-162 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  141. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

    Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Dührsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Merz, M., Baertsch, M-A., Jauch, A., Hose, D., Martin, H., Lindemann, H-W., Blau, I. W., Scheid, C., Weisel, K. C., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 01.2019, In: LEUKEMIA. 33, 1, p. 258-261 4 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  142. 2018
  143. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

    Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M-D., Bosi, A., Hungria, V., Cavo, M., Lee, J-J., Nooka, A. K., Quach, H., Lee, C., Barreto, W., Corradini, P., Min, C-K., Scott, E. C., Chanan-Khan, A. A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J-C., Shin, H-J., Sonneveld, P., Soong, D., Casneuf, T., Chiu, C., Amin, H., Qi, M., Thiyagarajah, P., Sasser, A. K., Schecter, J. M. & Mateos, M-V., 12.2018, In: HAEMATOLOGICA. 103, 12, p. 2079-2087 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  144. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

    Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., Signorovitch, J. E., Makenbaeva, D., Mekan, S., Sy, O., Weisel, K. & Richardson, P. G., 15.10.2018, In: CANCER-AM CANCER SOC. 124, 20, p. 4032-4043 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  145. Maintenance and continuous therapy for multiple myeloma

    Richardson, P. G., Laubach, J., Gandolfi, S., Facon, T., Weisel, K. & O'Gorman, P., 08.2018, In: EXPERT REV ANTICANC. 18, 8, p. 751-764 14 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  146. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

    Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., Di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 10.07.2018, In: J CLIN ONCOL. 36, 20, p. 2035-2043 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  147. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

    Moreau, P., Mateos, M-V., Berenson, J. R., Weisel, K., Lazzaro, A., Song, K., Dimopoulos, M. A., Huang, M., Zahlten-Kumeli, A. & Stewart, A. K., 07.2018, In: LANCET ONCOL. 19, 7, p. 953-964 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  148. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M-V., Cook, G., Leleu, X., Goldschmidt, H., Jackson, G., Kaiser, M., Weisel, K., van de Donk, N. W. C. J., Waage, A., Beksac, M., Mellqvist, U. H., Engelhardt, M., Caers, J., Driessen, C., Bladé, J. & Sonneveld, P., 07.2018, In: LEUKEMIA. 32, 7, p. 1542-1560 19 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  149. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

    Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W-J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S. & Dimopoulos, M. A., 06.2018, In: LEUKEMIA LYMPHOMA. 59, 6, p. 1364-1374 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  150. Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199]

    Schabel, C., Horger, M., Kum, S., Weisel, K., Fritz, J., Ioanoviciu, S. D. & Bier, G., 06.2018, In: EUR J RADIOL. 103, p. 163

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  151. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

    Holstein, S. A., Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K. & McCarthy, P. L., 04.2018, In: BIOL BLOOD MARROW TR. 24, 4, p. 641-648 8 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  152. Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma

    Horger, M., Fritz, J., Thaiss, W. M., Ditt, H., Weisel, K., Haap, M. & Kloth, C., 03.2018, In: SKELETAL RADIOL. 47, 3, p. 351-361 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  153. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

    Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., van Marwijk Kooy, M., Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, L., Salwender, H. J. & Sonneveld, P., 02.2018, In: LEUKEMIA. 32, 2, p. 383-390 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  154. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

    Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K. C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L. & Hulin, C., 18.01.2018, In: BLOOD. 131, 3, p. 301-310 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  155. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

    Merz, M., Jauch, A., Hielscher, T., Bochtler, T., Schönland, S. O., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Hillengass, J., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I. G. H., Scheid, C., Haenel, M., Weisel, K. C. & Goldschmidt, H., 09.01.2018, In: BLOOD ADV. 2, 1, p. 1-9 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  156. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

    Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengass, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K., Salwender, H. J., Hänel, M., Fenk, R., Dürig, J., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 2018, In: ONCOIMMUNOLOGY. 7, 10, p. e1486356

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  157. 2017
  158. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

    Schmitt, M., Hückelhoven, A. G., Hundemer, M., Schmitt, A., Lipp, S., Emde, M., Salwender, H., Hänel, M., Weisel, K., Bertsch, U., Dürig, J., Ho, A. D., Blau, I. W., Goldschmidt, H., Seckinger, A. & Hose, D., 17.10.2017, In: ONCOTARGET. 8, 49, p. 84847-84862 16 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  159. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

    Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W-J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., Aggarwal, S., Feng, S. & Joshua, D., 10.2017, In: LEUKEMIA LYMPHOMA. 58, 10, p. 2501-2504 4 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  160. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. & Moreau, P., 10.2017, In: LANCET ONCOL. 18, 10, p. 1327-1337 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  161. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    Moreau, P., Dimopoulos, M. A., Richardson, P. G., Siegel, D. S., Cavo, M., Corradini, P., Weisel, K., Delforge, M., O'Gorman, P., Song, K., Chen, C., Bahlis, N., Oriol, A., Hansson, M., Kaiser, M., Anttila, P., Raymakers, R., Joao, C., Cook, G., Sternas, L., Biyukov, T., Slaughter, A., Hong, K., Herring, J., Yu, X., Zaki, M. & San-Miguel, J., 09.2017, In: EUR J HAEMATOL. 99, 3, p. 199-206 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  162. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

    Huhn, S., Weinhold, N., Nickel, J., Pritsch, M., Hielscher, T., Hummel, M., Bertsch, U., Huegle-Doerr, B., Vogel, M., Angermund, R., Hänel, M., Salwender, H. J., Weisel, K., Dürig, J., Görner, M., Kirchner, H., Peter, N., Graeven, U., Lordick, F., Hoffmann, M., Reimer, P., Blau, I. W., Jauch, A., Dembowsky, K., Möhler, T., Wuchter, P. & Goldschmidt, H., 08.2017, In: BONE MARROW TRANSPL. 52, 8, p. 1194-1198 5 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  163. Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

    Merz, M., Jauch, A., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I., Scheid, C., Haenel, M., Weisel, K., Goldschmidt, H. & Hillengass, J., 08.2017, In: HAEMATOLOGICA. 102, 8, p. 1432-1438 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  164. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens: entity-specific dividing lines and "pan-leukemia" antigens

    Backert, L., Kowalewski, D. J., Walz, S., Schuster, H., Berlin, C., Neidert, M. C., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Kanz, L., Salih, H. R., Kohlbacher, O., Weisel, K., Rammensee, H-G., Stevanovic, S. & Walz, J. S., 04.07.2017, In: ONCOTARGET. 8, 27, p. 43915-43924 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  165. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

    Baertsch, M-A., Schlenzka, J., Lisenko, K., Krzykalla, J., Becker, N., Weisel, K., Noppeney, R., Martin, H., Lindemann, H. W., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I. G. H., Klein, S., Ho, A. D., Goldschmidt, H. & Wuchter, P., 07.2017, In: EUR J HAEMATOL. 99, 1, p. 42-50 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  166. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation

    Schneidawind, C., Duerr-Stoerzer, S., Faul, C., Kanz, L., Weisel, K., Bethge, W. & Schneidawind, D., 07.2017, In: CLIN TRANSPLANT. 31, 7

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  167. Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm

    Horger, M., Thaiss, W. M., Ditt, H., Weisel, K., Fritz, J., Nikolaou, K., Liao, S. & Kloth, C., 07.2017, In: EUR RADIOL. 27, 7, p. 2969-2977 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  168. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

    Chng, W-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., Feng, S., Aggarwal, S. & Hájek, R., 06.2017, In: LEUKEMIA. 31, 6, p. 1368-1374 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  169. Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma

    Horger, M., Ditt, H., Liao, S., Weisel, K., Fritz, J., Thaiss, W. M., Kaufmann, S., Nikolaou, K. & Kloth, C., 05.2017, In: ACAD RADIOL. 24, 5, p. 623-632 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  170. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

    Ludwig, H., Weisel, K., Petrucci, M. T., Leleu, X., Cafro, A. M., Garderet, L., Leitgeb, C., Foa, R., Greil, R., Yakoub-Agha, I., Zboralski, D., Vauléon, S., Dümmler, T., Beyer, D., Kruschinski, A., Riecke, K., Baumann, M. & Engelhardt, M., 04.2017, In: LEUKEMIA. 31, 4, p. 997-1000 4 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  171. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

    Weisel, K., Doyen, C., Dimopoulos, M., Yee, A., Lahuerta, J. J., Martin, A., Travers, K., Druyts, E., Toor, K., Abildgaard, N., Lu, J., Van Droogenbroeck, J., Geraldes, C., Petrini, M., Voillat, L., Voog, E. & Facon, T., 01.2017, In: LEUKEMIA LYMPHOMA. 58, 1, p. 153-161 9 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  172. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

    Moreau, P., Joshua, D., Chng, W-J., Palumbo, A., Goldschmidt, H., Hájek, R., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., Aggarwal, S., Feng, S. & Dimopoulos, M. A., 01.2017, In: LEUKEMIA. 31, 1, p. 115-122 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  173. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

    Li, Y., Wang, X., O'Mara, E., Dimopoulos, M. A., Sonneveld, P., Weisel, K. C., Matous, J., Siegel, D. S., Shah, J. J., Kueenburg, E., Sternas, L., Cavanaugh, C., Zaki, M., Palmisano, M. & Zhou, S., 2017, In: CLIN PHARMACOL-ADV A. 9, p. 133-145 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  174. 2016
  175. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

    Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, M., Brossart, P., Gerecke, C., Lindemann, H-W., Zeis, M., Weisel, K., Duerig, J. & Goldschmidt, H., 12.2016, In: HAEMATOLOGICA. 101, 12, p. e485-e487

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  176. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

    Siegel, D. S., Weisel, K. C., Dimopoulos, M. A., Baz, R., Richardson, P., Delforge, M., Song, K. W., San Miguel, J. F., Moreau, P., Goldschmidt, H., Cavo, M., Jagannath, S., Yu, X., Hong, K., Sternas, L., Zaki, M. & Palumbo, A., 12.2016, In: LEUKEMIA LYMPHOMA. 57, 12, p. 2833-2838 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  177. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

    Moreau, P., Weisel, K. C., Song, K. W., Gibson, C. J., Saunders, O., Sternas, L. A., Hong, K., Zaki, M. H. & Dimopoulos, M. A., 12.2016, In: LEUKEMIA LYMPHOMA. 57, 12, p. 2839-2847 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  178. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A., Sonneveld, P. & CASTOR Investigators, 25.08.2016, In: NEW ENGL J MED. 375, 8, p. 754-66 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  179. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

    Dimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., Blanchard, M. J., Goldschmidt, H., Doyen, C., Kaiser, M., Petrini, M., Anttila, P., Cafro, A. M., Raymakers, R., San-Miguel, J., de Arriba, F., Knop, S., Röllig, C., Ocio, E. M., Morgan, G., Miller, N., Simcock, M., Peluso, T., Herring, J., Sternas, L., Zaki, M. H. & Moreau, P., 28.07.2016, In: BLOOD. 128, 4, p. 497-503 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  180. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

    Weisel, K. C., Dimopoulos, M. A., Moreau, P., Lacy, M. Q., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Knop, S., Yu, X., Hong, K., Sternas, L., Jacques, C., Zaki, M. H. & San Miguel, J., 07.2016, In: HAEMATOLOGICA. 101, 7, p. 872-8 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  181. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

    Baertsch, M-A., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M. S., Hose, D., Wuchter, P., Ho, A. D., Jauch, A., Hielscher, T., Kunz, C., Luntz, S., Klein, S., Schmidt-Wolf, I. G. H., Goerner, M., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Salwender, H., Scheid, C., Nogai, A., Haenel, M., Lindemann, H. W., Martin, H., Noppeney, R., Weisel, K. & Goldschmidt, H., 25.04.2016, In: BMC CANCER. 16, p. 290

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  182. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini

    Kowalewski, D. J., Walz, S., Backert, L., Schuster, H., Kohlbacher, O., Weisel, K., Rittig, S. M., Kanz, L., Salih, H. R., Rammensee, H-G., Stevanović, S. & Stickel, J. S., 08.04.2016, In: BLOOD CANCER J. 6, p. e411

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  183. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

    Weinhold, N., Kirn, D., Seckinger, A., Hielscher, T., Granzow, M., Bertsch, U., Egerer, G., Salwender, H., Blau, I. W., Weisel, K., Hillengass, J., Raab, M. S., Hose, D., Goldschmidt, H. & Jauch, A., 03.2016, In: HAEMATOLOGICA. 101, 3, p. e116-9

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  184. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A., Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S., Chng, W-J. & ENDEAVOR Investigators, 01.2016, In: LANCET ONCOL. 17, 1, p. 27-38 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  185. Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned

    Bier, G., Mustafa, D. F., Kloth, C., Weisel, K., Ditt, H., Nikolaou, K. & Horger, M., 01.2016, In: AM J ROENTGENOL. 206, 1, p. 57-63 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  186. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

    Weisel, K., 2016, In: ONCOTARGETS THER. 9, p. 6037-6048 12 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  187. 2015
  188. Development and Validation of A Conceptual Model of Multiple Myeloma

    Gonzalez-McQuire, S., Campioni, M., Bennison, C., Xu, W., Pantiri, K., Hensen, M., Weisel, K., Terpos, E. & Knop, S., 11.2015, In: VALUE HEALTH. 18, 7, p. A698

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  189. Development of A Conceptual Model of Multiple Myeloma for Use In Economic Modelling: A Systematic Literature Review to Identify The Evidence Base

    Gonzalez-McQuire, S., Campioni, M., Bennison, C., Xu, W., Pantiri, K., Hensen, M., Weisel, K., Terpos, E. & Knop, S., 11.2015, In: VALUE HEALTH. 18, 7, p. A701

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  190. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Dimopoulos, M. A., Weisel, K. C., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Banos, A., Oriol, A., Garderet, L., Cavo, M., Ivanova, V., Alegre, A., Martinez-Lopez, J., Chen, C., Spencer, A., Knop, S., Bahlis, N. J., Renner, C., Yu, X., Hong, K., Sternas, L., Jacques, C., Zaki, M. H. & San Miguel, J. F., 10.2015, In: HAEMATOLOGICA. 100, 10, p. 1327-33 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  191. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    San Miguel, J. F., Weisel, K. C., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Banos, A., Oriol, A., Garderet, L., Cavo, M., Ivanova, V., Alegre, A., Martinez-Lopez, J., Chen, C., Renner, C., Bahlis, N. J., Yu, X., Teasdale, T., Sternas, L., Jacques, C., Zaki, M. H. & Dimopoulos, M. A., 10.2015, In: HAEMATOLOGICA. 100, 10, p. 1334-9 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  192. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

    Walz, S., Stickel, J. S., Kowalewski, D. J., Schuster, H., Weisel, K., Backert, L., Kahn, S., Nelde, A., Stroh, T., Handel, M., Kohlbacher, O., Kanz, L., Salih, H. R., Rammensee, H-G. & Stevanović, S., 03.09.2015, In: BLOOD. 126, 10, p. 1203-13 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  193. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

    Weisel, K., Dimopoulos, M., Song, K. W., Moreau, P., Palumbo, A., Belch, A., Schey, S., Sonneveld, P., Sternas, L., Yu, X., Amatya, R., Gibson, C. J., Zaki, M., Jacques, C. & San Miguel, J., 09.2015, In: CL LYMPH MYELOM LEUK. 15, 9, p. 519-30 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  194. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

    Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W., Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. & Goldschmidt, H., 08.2015, In: LEUKEMIA. 29, 8, p. 1721-9 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  195. Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images

    Homann, G., Weisel, K., Mustafa, D. F., Ditt, H., Nikolaou, K. & Horger, M., 07.2015, In: SKELETAL RADIOL. 44, 7, p. 971-9 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  196. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

    Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, M., Schmidt-Wolf, I. G. H., Gerecke, C., Lindemann, H-W., Zeis, M., Weisel, K., Duerig, J. & Goldschmidt, H., 07.2015, In: HAEMATOLOGICA. 100, 7, p. 964-9 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  197. Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma

    Thomas, C., Schabel, C., Krauss, B., Weisel, K., Bongers, M., Claussen, C. D. & Horger, M., 03.2015, In: AM J ROENTGENOL. 204, 3, p. W324-31

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  198. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

    Morgan, G., Palumbo, A., Dhanasiri, S., Lee, D., Weisel, K., Facon, T., Delforge, M., Oriol, A., Zaki, M., Yu, X., Sternas, L., Jacques, C., Akehurst, R., Offner, F. & Dimopoulos, M. A., 03.2015, In: BRIT J HAEMATOL. 168, 6, p. 820-3 4 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  199. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

    Weinstock, C., Möhle, R., Dorn, C., Weisel, K., Höchsmann, B., Schrezenmeier, H. & Kanz, L., 03.2015, In: TRANSFUSION. 55, 3, p. 605-10 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  200. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

    Song, K. W., Dimopoulos, M. A., Weisel, K. C., Moreau, P., Palumbo, A., Belch, A., Schey, S., Sonneveld, P., Sternas, L., Yu, X., Amatya, R., Monzini, M. S., Zaki, M., Jacques, C. & San Miguel, J., 02.2015, In: HAEMATOLOGICA. 100, 2, p. e63-7

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  201. 2014
  202. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment

    Zago, M., Oehrlein, K., Rendl, C., Hahn-Ast, C., Kanz, L. & Weisel, K., 12.2014, In: ANN HEMATOL. 93, 12, p. 1993-9 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  203. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., Facon, T. & FIRST Trial Team, 04.09.2014, In: NEW ENGL J MED. 371, 10, p. 906-17 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  204. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

    Dimopoulos, M. A., Leleu, X., Palumbo, A., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., Schey, S. A., Zweegman, S., Hansson, M., Weisel, K., Mateos, M. V., Facon, T. & Miguel, J. F. S., 08.2014, In: LEUKEMIA. 28, 8, p. 1573-85 13 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  205. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

    Dorn, C., Bugl, S., Malenke, E., Müller, M. R., Weisel, K. C., Vogel, U., Horger, M., Kanz, L. & Kopp, H-G., 23.05.2014, In: BMC RES NOTES. 7, p. 313

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  206. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era

    Zago, M., Adam, P., Goldschmidt, H., Fend, F., Kanz, L. & Weisel, K., 02.2014, In: CL LYMPH MYELOM LEUK. 14, 1, p. e7-e11

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  207. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

    Scheid, C., Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Blau, I. W., Vellenga, E., Weisel, K., Pfreundschuh, M., Jie, K-S., Neben, K., van de Velde, H., Duehrsen, U., Schaafsma, M. R., Lindemann, W., Kersten, M. J., Peter, N., Hänel, M., Croockewit, S., Martin, H., Wittebol, S., Bos, G. M., van Marwijk-Kooy, M., Wijermans, P., Goldschmidt, H. & Lokhorst, H. M., 01.2014, In: HAEMATOLOGICA. 99, 1, p. 148-54 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  208. Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study

    Schulze, M., Weisel, K., Grandjean, C., Oehrlein, K., Zago, M., Spira, D. & Horger, M., 01.2014, In: AM J ROENTGENOL. 202, 1, p. 170-9 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  209. 2013
  210. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M., 10.2013, In: LANCET ONCOL. 14, 11, p. 1055-1066 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  211. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data

    Pintoffl, J. P., Weisel, K., Schulze, M., Maksimovic, O., Claussen, C. D., Kramer, U. & Horger, M., 10.2013, In: J ULTRAS MED. 32, 10, p. 1777-88 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  212. The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas

    Adam, P., Baumann, R., Schmidt, J., Bettio, S., Weisel, K., Bonzheim, I., Fend, F. & Quintanilla-Martínez, L., 09.2013, In: HUM PATHOL. 44, 9, p. 1817-26 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  213. Cutaneous presentation of hematological malignancies

    Eberle, F. C., Metzler, G., Weisel, K. C., Berneburg, M. & Yazdi, A. S., 21.06.2013, In: EUR J DERMATOL. 23, 3, p. 372-7 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  214. 2012
  215. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial

    Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., Weisel, K. C., Wittebol, S., Bos, G. M. J., Stevens-Kroef, M., Scheid, C., Pfreundschuh, M., Hose, D., Jauch, A., van der Velde, H., Raymakers, R., Schaafsma, M. R., Kersten, M-J., van Marwijk-Kooy, M., Duehrsen, U., Lindemann, W., Wijermans, P. W., Lokhorst, H. M. & Goldschmidt, H. M., 20.08.2012, In: J CLIN ONCOL. 30, 24, p. 2946-55 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  216. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation

    Guthoff, M., Schmid-Horch, B., Weisel, K. C., Häring, H-U., Königsrainer, A. & Heyne, N., 06.2012, In: TRANSPL IMMUNOL. 26, 4, p. 171-5 5 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  217. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers

    Oehrlein, K., Langer, C., Sturm, I., Pönisch, W., Hahn-Ast, C., Kuhn, S. & Weisel, K. C., 06.2012, In: CL LYMPH MYELOM LEUK. 12, 3, p. 191-6 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  218. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

    Auel, B., Goldschmidt, H., Geer, T., Moehler, T. M., Platzbecker, U., Naumann, R., Blau, I., Hänel, M., Knauf, W., Nückel, H., Salwender, H-J., Scheid, C., Weisel, K., Gorschlüter, M., Glasmacher, A., Schmidt-Wolf, I. G. H. & German Refractory Myeloma Study Group, 06.2012, In: INDIAN J HEMATOL BLO. 28, 2, p. 67-76 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  219. Continuous lenalidomide treatment for newly diagnosed multiple myeloma

    Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., Cascavilla, N., Iosava, G., Cavo, M., Kloczko, J., Bladé, J., Beksac, M., Spicka, I., Plesner, T., Radke, J., Langer, C., Ben Yehuda, D., Corso, A., Herbein, L., Yu, Z., Mei, J., Jacques, C., Dimopoulos, M. A. & MM-015 Investigators, 10.05.2012, In: NEW ENGL J MED. 366, 19, p. 1759-69 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  220. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

    Heyne, N., Denecke, B., Guthoff, M., Oehrlein, K., Kanz, L., Häring, H-U. & Weisel, K. C., 05.2012, In: ANN HEMATOL. 91, 5, p. 729-735 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  221. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., Scheid, C., Dührsen, U., Lindemann, W., Schmidt-Wolf, I. G. H., Peter, N., Teschendorf, C., Martin, H., Haenel, M., Derigs, H. G., Raab, M. S., Ho, A. D., van de Velde, H., Hose, D., Sonneveld, P. & Goldschmidt, H., 26.01.2012, In: BLOOD. 119, 4, p. 940-8 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  222. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

    Spira, D., Weisel, K., Brodoefel, H., Schulze, M., Kaufmann, S. & Horger, M., 01.2012, In: ACAD RADIOL. 19, 1, p. 89-94 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  223. Osteoprotegerin positively regulates hematopoietic progenitor cells

    Schweikle, E., Baessler, T., Yildirim, S., Kanz, L., Möhle, R. & Weisel, K. C., 01.2012, In: CURR STEM CELL RES T. 7, 1, p. 72-7 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  224. 2011
  225. Modern imaging techniques during therapy in patients with multiple myeloma

    Horger, M., Weisel, K., Bares, R., Ernemann, U., Claussen, C. D., Lichy, M. & Fenchel, M., 01.10.2011, In: ACTA RADIOL. 52, 8, p. 881-8 8 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  226. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results

    Horger, M., Weisel, K., Horger, W., Mroue, A., Fenchel, M. & Lichy, M., 06.2011, In: AM J ROENTGENOL. 196, 6, p. W790-5

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  227. 2010
  228. Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results

    Fenchel, M., Konaktchieva, M., Weisel, K., Kraus, S., Brodoefel, H., Claussen, C. D. & Horger, M., 12.2010, In: EUR RADIOL. 20, 12, p. 2899-906 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  229. Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study

    Fenchel, M., Konaktchieva, M., Weisel, K., Kraus, S., Claussen, C. D. & Horger, M., 11.2010, In: ACAD RADIOL. 17, 11, p. 1326-33 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  230. Imaging findings in relapsing multiple myeloma

    Sauter, A., Weisel, K. & Horger, M., 08.2010, In: BRIT J HAEMATOL. 150, 4, p. 388

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  231. Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells

    Weisel, K. C., Kopp, H-G., Moore, M. A. S., Studer, L. & Barberi, T., 05.2010, In: STEM CELLS DEV. 19, 5, p. 745-51 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  232. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

    Weidmann, E., Hess, G., Chow, K. U., Krause, S. W., Subklewe, M., Kruse, J., Weisel, K. C., Soekler, M., Kim, S-Z., Napieralski, S., Rech, J., Dreyling, M., Jäger, E. & Mitrou, P. S., 03.2010, In: LEUKEMIA LYMPHOMA. 51, 3, p. 447-55 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  233. 2009
  234. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

    Kropff, M., Liebisch, P., Knop, S., Weisel, K., Wand, H., Gann, C-N., Berdel, W. E., Einsele, H. & Deutsche Studiengruppe Multiples Myelom, DSMM, 11.2009, In: ANN HEMATOL. 88, 11, p. 1125-30 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  235. Severe psychotic disorder and agranulocytosis--a therapeutic dilemma

    Borbé, R., Weisel, K., Sachs, U. J. H. & Steinert, T., 11.2009, In: PHARMACOPSYCHIATRY. 42, 6, p. 284-5 2 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  236. Rhabdomyolysis and acute kidney injury

    Heyne, N., Guthoff, M. & Weisel, K. C., 01.10.2009, In: NEW ENGL J MED. 361, 14, p. 1412; author reply 1412-3

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  237. International Symposium and Workshop on hematopoietic stem cells VII, University of Tübingen, Germany, September 18-20, 2008

    Weisel, K. C., Dick, J., Fibbe, W. E. & Kanz, L., 09.2009, In: ANN NY ACAD SCI. 1176, p. 1-17 17 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  238. Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease

    Vogel, M. N., Weisel, K., Maksimovic, O., Peters, S., Brodoefel, H., Claussen, C. D. & Horger, M. S., 09.2009, In: AM J ROENTGENOL. 193, 3, p. 656-61 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  239. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma

    Kopp, H. G., Yildirim, S., Weisel, K. C., Kanz, L. & Vogel, W., 04.2009, In: J CANCER RES CLIN. 135, 4, p. 637-42 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  240. Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support

    Weisel, K. C., Moore, M. A. S., Kanz, L. & Möhle, R., 03.2009, In: STEM CELLS DEV. 18, 2, p. 229-34 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  241. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells

    Weisel, K. C., Yildirim, S., Schweikle, E., Kanz, L. & Möhle, R., 03.2009, In: ANN HEMATOL. 88, 3, p. 203-11 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  242. Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide

    Weisel, K. C., Böckeler, M., Bianchi, L., Terracciano, L. M., Mayer, F. & Kanz, L., 01.2009, In: International journal of hematology. 89, 1, p. 91-94 4 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  243. Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation

    Weisel, K. C., Bautz, F., Seitz, G., Yildirim, S., Kanz, L. & Möhle, R., 2009, In: MEDIAT INFLAMM. 2009, p. 790174

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  244. 2008
  245. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma

    Weisel, K. C., Weidmann, E., Anagnostopoulos, I., Kanz, L., Pezzutto, A. & Subklewe, M., 11.2008, In: International journal of hematology. 88, 4, p. 434-440 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  246. OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells

    Ji, J., Vijayaragavan, K., Bosse, M., Menendez, P., Weisel, K. & Bhatia, M., 10.2008, In: Stem cells (Dayton, Ohio). 26, 10, p. 2485-95 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  247. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial

    Hutchison, C. A., Cook, M., Heyne, N., Weisel, K., Billingham, L., Bradwell, A. & Cockwell, P., 28.09.2008, In: TRIALS. 9, p. 55

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  248. 2007
  249. Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells VI, University of Tübingen, Germany, September 14-16, 2006

    Weisel, K. C., Fibbe, W. E. & Kanz, L., 07.2007, In: Experimental hematology. 35, 7, p. 1005-14 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearch

  250. Differential effects of G protein coupled receptors on hematopoietic progenitor cell growth depend on their signaling capacities

    Xue, X., Cai, Z., Seitz, G., Kanz, L., Weisel, K. C. & Möhle, R., 06.2007, In: ANN NY ACAD SCI. 1106, p. 180-9 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearch

  251. Effect of FLT3 inhibition on normal hematopoietic progenitor cells

    Weisel, K. C., Yildirim, S., Schweikle, E., Kanz, L. & Möhle, R., 06.2007, In: ANN NY ACAD SCI. 1106, p. 190-6 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearch

  252. 2006
  253. Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma

    Hartmann, J. T., Meisinger, I., Kröber, S. M., Weisel, K., Klingel, K. & Kanz, L., 12.2006, In: HAEMATOLOGICA. 91, 12 Suppl, p. ECR49

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  254. Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis

    Weisel, K. C., Gao, Y., Shieh, J-H. & Moore, M. A. S., 11.2006, In: Experimental hematology. 34, 11, p. 1505-16 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  255. 2005
  256. Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region

    Weisel, K. C. & Moore, M. A. S., 06.2005, In: ANN NY ACAD SCI. 1044, p. 51-9 9 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  257. Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells V, University of Tübingen, Germany, September 16-18, 2004

    Weisel, K. C., Brümmendorf, T. H., Orlic, D., Fibbe, W. E. & Kanz, L., 05.2005, In: Experimental hematology. 33, 5, p. 513-22 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearch

  258. 2004
  259. Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication

    Gammaitoni, L., Weisel, K. C., Gunetti, M., Wu, K-D., Bruno, S., Pinelli, S., Bonati, A., Aglietta, M., Moore, M. A. S. & Piacibello, W., 15.06.2004, In: BLOOD. 103, 12, p. 4440-8 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  260. Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders

    Weisel, K. C., Brugger, W., Kröber, S. M., Kaiserling, E. & Kanz, L., 2004, In: HEMATOL J. 5, 5, p. 444-6 3 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review